Ubc13 Promotes K63-Linked Polyubiquitination of NLRP3 to Activate Inflammasome.

Jun Ni,Chenyang Guan,Hua Liu,Xian Huang,Jinnan Yue,Hongrui Xiang,Zhenyan Jiang,Yuexiao Tao,Wenyi Cao,Jiamin Liu,Zhengting Wang,Yugang Wang,Xuefeng Wu
DOI: https://doi.org/10.4049/jimmunol.2001178
2021-01-01
The Journal of Immunology
Abstract:NLRP3 inflammasome plays an important role in innate immune system through recognizing pathogenic microorganisms and danger-associated molecules. Deubiquitination of NLRP3 has been shown to be essential for its activation, yet the functions of Ubc13, the K63-linked specific ubiquitin-conjugating enzyme E2, in NLRP3 inflammasome activation are not known. In this study, we found that in mouse macrophages, Ubc13 knockdown or knockout dramatically impaired NLRP3 inflammasome activation. Catalytic activity is required for Ubc13 to control NLRP3 activation, and Ubc13 pharmacological inhibitor significantly attenuates NLRP3 inflammasome activation. Mechanistically, Ubc13 associates with NLRP3 and promotes its K63-linked polyubiquitination. Through mass spectrum and biochemical analysis, we identified lysine 565 and lysine 687 as theK63-linked polyubiquitination sites of NLRP3. Collectively, our data suggest that Ubc13 potentiates NLRP3 inflammasome activation via promoting site-specific K63-linked ubiquitination of NLRP3. Our study sheds light on mechanisms of NLRP3 inflammasome activation and identifies that targeting Ubc13 could be an effective therapeutic strategy for treating aberrant NLRP3 inflammasome activation-induced pathogenesis.
What problem does this paper attempt to address?